RxDoctor Payments Data

Magdalena Chavez, PA

Physician Assistant · Bedford, TXNPI 1841680238

Payments from drug & device makers

$3,987in general payments, 2019–2025

Across 149 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • AbbVie$676
  • Boehringer Ingelheim$434
  • GSK$398
  • Lilly USA, LLC$275
  • Novo Nordisk$157
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$80020%
  • Food & beverage$3,18780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,987 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$19,877
Medicare patients
69
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$38,312
EliquisApixaban33$26,789
JardianceEmpagliflozin11$17,904
OzempicSemaglutide14$14,926
JanuviaSitagliptin Phosphate16$11,762
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,314
Atorvastatin Calcium185$1,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,299
Rosuvastatin Calcium105$1,163
Albuterol Sulfate HfaAlbuterol Sulfate40$980
Levothyroxine Sodium82$721
Amlodipine Besylate107$650
Bupropion XlBupropion Hcl25$624
Metformin Hcl ErMetformin Hcl74$520
Levetiracetam12$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$398$44,62664 claims
PfizerEliquis$147$26,78933 claims
Boehringer IngelheimJardiance$434$17,90411 claims
Novo NordiskOzempic$157$14,92614 claims
MerckJanuvia$39$11,76216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →